Results 91 to 100 of about 46,179 (165)

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity. [PDF]

Front Cardiovasc Med
Pala B, Piscione M, Di Marcantonio MC, Cribari F, Vitale R, Baldi T, Popolo A, Mincione G.   +7 more
europepmc   +1 more source

Cardiotoxicity prevention trials in the era of contemporary cancer therapies: a systematic review. [PDF]

Cardiooncology
Munir M, Sayed A, Ghazi S, Yang EH, Guha A, Epperla N, Addison D.   +6 more
europepmc   +1 more source

Editorial: Cardiomyopathy and heart failure in oncology. [PDF]

Front Oncol
Adamiak M, Borowiec A, Kalyanasundaram A, Mathiyalagan P.   +3 more
europepmc   +1 more source

Design, Synthesis, and Protective Activity against Doxorubicin-Induced Cardiotoxicity of Novel Water-Soluble Small-Molecule GPx Mimics. [PDF]

ACS Med Chem Lett
Yu Z, Shi W, Qian Z, Mei X, Huang X, Chen X, Wang W, Zhang T, Chen X, Li Z, Zheng C.   +10 more
europepmc   +1 more source

Current Perspectives in Cardio-oncology: Insights from Global Experts. [PDF]

Eur Cardiol
Leo L, Camilli M.
europepmc   +1 more source

Incidence of cardiotoxicity assessed with CZT-ERNA in patients undergoing contemporary cancer therapy: a 12-year real-world experience. [PDF]

Cardiooncology
Larsson JE, Nielsen MØ, Zerahn B.
europepmc   +1 more source

Determining oncology nurses' awareness of cardio-oncology in Türkiye: A descriptive study. [PDF]

Asia Pac J Oncol Nurs
Kalkan Uğurlu Y, Türen S, Karaçam E, Lee G.   +3 more
europepmc   +1 more source

Knowledge structure and thematic organization of PFAS-associated cardiac toxicity: A bibliometric analysis. [PDF]

Toxicol Rep
Azman M', Abd Latip N.
europepmc   +1 more source